bendamustine hydrochloride monohydrate
PolandDrugs containing this active substance
-
The medicinal product is used for the treatment of chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma.
Form: powder for preparation of concentrate for infusion solution
Active substance Dosage bendamustine hydrochloride monohydrate 25 mg/vial or 100 mg/vial ATC: L01AA09
Manufacturer: Accompagny Healthcare Polska Ltd.
-
The medicinal product is used to treat certain types of cancer: chronic lymphocytic leukaemia, non-Hodgkin lymphoma, and multiple myeloma.
Form: solution for infusion, concentrate
Active substance Dosage bendamustine hydrochloride monohydrate 26.14 mg/ml ATC: L01AA09
Manufacturer: Accompagny Healthcare Polska Ltd.
-
The medicinal product is used to treat certain types of cancer: chronic lymphocytic leukemia (when fludarabine chemotherapy is not indicated), non-Hodgkin lymphomas (which have not responded adequately to rituximab), and multiple myeloma (when treatment with thalidomide or bortezomib is inappropriate).
Form: powder for preparation of concentrate for infusion solution
Active substance Dosage bendamustine hydrochloride monohydrate 2.5 mg/ml ATC: L01AA09
Manufacturer: APL Swift Services (Malta) Ltd. Arrow Generiques Generis Farmacêutica, S.A.
-
The medicinal product is used to treat certain types of cancer: chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma.
Form: powder for preparation of concentrate for infusion solution
Active substance Dosage bendamustine hydrochloride monohydrate 25 mg/vial or 100 mg/vial ATC: L01AA09
Manufacturer: Synthon Hispania S.L. Synthon s.r.o.
-
The medicinal product is used to treat certain types of cancer: chronic lymphocytic leukemia, non-Hodgkin lymphoma, and multiple myeloma.
Form: powder for preparation of concentrate for infusion solution
Active substance Dosage bendamustine hydrochloride monohydrate 26.1 mg or 104.6 mg ATC: L01AA09
Manufacturer: Synthon Hispania S.L. Synthon s.r.o.